Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
| العنوان: | Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma |
|---|---|
| المؤلفون: | Lihua E. Budde, Ted Gooley, Ajay K. Gopal, Brian G. Till, Adam Greenbaum, Oliver W. Press, Leona Holmberg, Damian J. Green, Heather A. Rasmussen |
| المصدر: | Blood research |
| بيانات النشر: | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Bendamustine, Oncology, medicine.medical_specialty, Follicular lymphoma, Filgrastim, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Autologous transplantation, Etoposide, Non-Hodgkin lymphoma, business.industry, Hematology, medicine.disease, 3. Good health, Lymphoma, Tumor lysis syndrome, 030220 oncology & carcinogenesis, Stem cell mobilization, Original Article, Stem cell, business, 030215 immunology, medicine.drug |
| الوصف: | Background Bendamustine is a chemotherapeutic agent that has shown broad activity in patients with lymphoid malignancies. It contains both alkylating and nucleoside analog moieties, and thus, is not commonly used for stem cell mobilization due to concerns that it may adversely affect stem cell collection. Here we describe the lymphoma subset of a prospective, non-randomized phase II study of bendamustine, etoposide, and dexamethasone (BED) as a mobilization agent for lymphoid malignancies. Methods This subset analysis includes diffuse large B-cell lymphoma (N=3), follicular lymphoma (N=1), primary mediastinal B-cell lymphoma (N=1), and NK/T-cell lymphoma (N=1). Patients received bendamustine (120 mg/m2 IV d 1, 2), etoposide (200 mg/m2 IV d 1-3), and dexamethasone (40 mg PO d 1-4) followed by filgrastim (10 mcg/kg/d sc. through collection). Results We successfully collected stem cells from all patients, with a median of 7.9×106/kg of body weight (range, 4.4 to 17.3×106/kg) over a median of 1.5 days (range, 1 to 3) of apheresis. All patients who received transplants were engrafted using kinetics that were comparable to those of other mobilization regimens. Three non-hematologic significant adverse events were observed in one patient, and included bacterial sepsis (grade 3), tumor lysis syndrome (grade 3), and disease progression (grade 5). Conclusion For non-Hodgkin lymphoma, mobilization with bendamustine is safe and effective. |
| اللغة: | English |
| تدمد: | 2288-0011 2287-979X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4a4f7ad511e5c76908b2d52009e288eTest http://europepmc.org/articles/PMC6170297Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e4a4f7ad511e5c76908b2d52009e288e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22880011 2287979X |
|---|